260 related articles for article (PubMed ID: 22294626)
21. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.
Sato S; Murakami A; Kuwajima A; Takehara K; Mimori T; Kawakami A; Mishima M; Suda T; Seishima M; Fujimoto M; Kuwana M
PLoS One; 2016; 11(4):e0154285. PubMed ID: 27115353
[TBL] [Abstract][Full Text] [Related]
22. Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice.
Mariscal A; Milán M; Baucells A; Martínez MA; Guillen AG; Trallero-Araguás E; Alvarado-Cardenas M; Martínez-Martínez L; Alserawan L; Franco-Leyva T; Sanz-Martínez MT; Viñas-Giménez L; Corominas H; Juárez C; Castellví I; Selva-O'Callaghan A
Front Immunol; 2020; 11():625896. PubMed ID: 33613568
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy.
Kaji K; Fujimoto M; Hasegawa M; Kondo M; Saito Y; Komura K; Matsushita T; Orito H; Hamaguchi Y; Yanaba K; Itoh M; Asano Y; Seishima M; Ogawa F; Sato S; Takehara K
Rheumatology (Oxford); 2007 Jan; 46(1):25-8. PubMed ID: 16728436
[TBL] [Abstract][Full Text] [Related]
24. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis.
Gunawardena H; Wedderburn LR; North J; Betteridge Z; Dunphy J; Chinoy H; Davidson JE; Cooper RG; McHugh NJ;
Rheumatology (Oxford); 2008 Mar; 47(3):324-8. PubMed ID: 18238791
[TBL] [Abstract][Full Text] [Related]
25. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
Okiyama N; Ichimura Y; Shobo M; Tanaka R; Kubota N; Saito A; Ishitsuka Y; Watanabe R; Fujisawa Y; Nakamura Y; Murakami A; Kayama H; Takeda K; Fujimoto M
Ann Rheum Dis; 2021 Sep; 80(9):1201-1208. PubMed ID: 33811031
[TBL] [Abstract][Full Text] [Related]
26. Distinct dermatomyositis populations are detected with different autoantibody assay platforms.
Fiorentino DF; Gutierrez-Alamillo L; Hines D; Yang Q; Casciola-Rosen L
Clin Exp Rheumatol; 2019; 37(6):1048-1051. PubMed ID: 31376258
[TBL] [Abstract][Full Text] [Related]
27. TIF1γ-overexpressing, highly progressive endometrial carcinoma in a patient with dermato-myositis positive for malignancy-associated anti-p155/140 autoantibody.
Kasuya A; Hamaguchi Y; Fujimoto M; Tokura Y
Acta Derm Venereol; 2013 Nov; 93(6):715-6. PubMed ID: 23407650
[No Abstract] [Full Text] [Related]
28. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis.
Sato S; Hirakata M; Kuwana M; Suwa A; Inada S; Mimori T; Nishikawa T; Oddis CV; Ikeda Y
Arthritis Rheum; 2005 May; 52(5):1571-6. PubMed ID: 15880816
[TBL] [Abstract][Full Text] [Related]
29. [Reliability and clinical utility of Enzyme-linked immunosorbent assay for detection of anti-aminoacyl-tRNA synthetase antibody].
Abe T; Tsunoda S; Nishioka A; Azuma K; Tsuboi K; Ogita C; Yokoyama Y; Furukawa T; Maruoka M; Tamura M; Yoshikawa T; Saito A; Sekiguchi M; Azuma N; Kitano M; Matsui K; Hosono Y; Nakashima R; Ohmura K; Mimori T; Sano H
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(2):140-4. PubMed ID: 27212600
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis.
Trallero-Araguás E; Rodrigo-Pendás JÁ; Selva-O'Callaghan A; Martínez-Gómez X; Bosch X; Labrador-Horrillo M; Grau-Junyent JM; Vilardell-Tarrés M
Arthritis Rheum; 2012 Feb; 64(2):523-32. PubMed ID: 21953614
[TBL] [Abstract][Full Text] [Related]
31. Autoantibodies against TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical significance and diagnostic utility.
Cuesta-Mateos C; Colom-Fernández B; Portero-Sainz I; Tejedor R; García-García C; Concha-Garzón MJ; De las Heras-Alonso ME; Martínez MA; Juarez C; Muñoz-Calleja C
J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):482-9. PubMed ID: 25065441
[TBL] [Abstract][Full Text] [Related]
32. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
33. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
34. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
[TBL] [Abstract][Full Text] [Related]
35. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy.
Trallero-Araguás E; Labrador-Horrillo M; Selva-O'Callaghan A; Martínez MA; Martínez-Gómez X; Palou E; Rodriguez-Sanchez JL; Vilardell-Tarrés M
Medicine (Baltimore); 2010 Jan; 89(1):47-52. PubMed ID: 20075704
[TBL] [Abstract][Full Text] [Related]
36. Clinical implications of autoantibody screening in patients with autoimmune myositis.
Ghirardello A; Zampieri S; Tarricone E; Iaccarino L; Bendo R; Briani C; Rondinone R; Sarzi-Puttini P; Todesco S; Doria A
Autoimmunity; 2006 May; 39(3):217-21. PubMed ID: 16769655
[TBL] [Abstract][Full Text] [Related]
37. [Retrospective analysis of anti-TIF1gamma, anti-NXP2 and anti-SAE1/2 antibodies carriers at Bordeaux university hospital from November 2014 to February 2017].
Victor J; Zanardo L; Héron-Mermin D; Poursac N; Solé G; Bordes C; Duffau P
Rev Med Interne; 2019 Feb; 40(2):70-81. PubMed ID: 30527961
[TBL] [Abstract][Full Text] [Related]
38. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.
Hosono Y; Sie B; Pinal-Fernandez I; Pak K; Mecoli CA; Casal-Dominguez M; Warner BM; Kaplan MJ; Albayda J; Danoff S; Lloyd TE; Paik JJ; Tiniakou E; Aggarwal R; Oddis CV; Moghadam-Kia S; Carmona-Rivera C; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Christopher-Stine L; Larman HB; Mammen AL
Ann Rheum Dis; 2023 Feb; 82(2):246-252. PubMed ID: 36008132
[TBL] [Abstract][Full Text] [Related]
39. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.
Ono R; Kumagae T; Igasaki M; Murata T; Yoshizawa M; Kitagawa I
J Med Case Rep; 2021 Mar; 15(1):142. PubMed ID: 33745453
[TBL] [Abstract][Full Text] [Related]
40. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients.
Muro Y; Sugiura K; Akiyama M
Autoimmunity; 2013 Jun; 46(4):279-84. PubMed ID: 23215730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
